Cardio- and nephroprotective mechanisms of SGLT2 inhibition

Conditions

I50.1 N18

Frederick Sinha, Susanne Klatt, Álvaro Rietmann, Anna Schoepperl, Sebastian Born et al. (8 authors)

Circulation2024-11-12

10.1161/circ.150.suppl_1.4137996

Abstract 4145037: Effects of Empagliflozin on cardio-renal interaction in heart failure: Results from the CINNAMON-study and in-vivo experiments

Frederick Sinha, Susanne Klatt, Álvaro Rietmann, Anna Schoepperl, Sebastian Born et al. (8 authors)

Circulation2024-11-12

10.1161/circ.150.suppl_1.4145037

Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

Frederick Sinha, Susanne Klatt, Álvaro Rietmann, Anna Schoepperl, Lars S. Maier et al. (7 authors)

European Heart Journal2024-10-01

10.1093/eurheartj/ehae666.3763

Interventions

Group 1: Patients with symptomatic heart failure and chronic renal disease stage G3a-G4

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Symptomatic heart failure - nt-pro-BNP > 125 pg/mL - Chronic renal failure stage G3a-G4 (GFR 15-59 mL/min) - No or only mild albuminuria: UACR < 100 mg/g

Exclusion criteria

Exclusion criteria: - Pre-existing therapy with SGLT2 inhibitor (SGLT2i) - Severe symptomatic lung disease - Autoimmune diseases - Higher grade valvular disease - Anemia (hemoglobin 150 mmHg or o Diastolic blood pressure > 100 mgHg or o > 3 antihypertensive medications.

Design outcomes

Primary

Measure	Time frame
Increase in albuminuria within 6 months of initiation of therapy with empagliflozin	—

Secondary

Measure	Time frame
Change in glomerular filtration rate Change in quality of life (KCCQ TSS)	—

Countries

Germany

Contacts

Public ContactStefan Wagner

Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II

stefan.wagner@ukr.de+49-941-944-7206

Outcome results

None listed